® (reslizumab) Injection
Teva Support Solutions
® offers resources to support healthcare providers with the individualized dosing requirements for CINQAIR ®.
Medication Administration Instruction
Our Clinical Nurse Educators can provide personalized education and training, including medication administration instruction.
Infusion Site Location Assistance
Teva Support Solutions
® can help healthcare providers locate an infusion site that is convenient to a patient’s home or office by using the Teva National Infusion Site Directory.
To obtain information about enrolled infusion sites, contact a Case Administrator at
Monday through Friday from 9 am to 7 pm ET. 1-844-838-2211,
Enrolling in the Teva National Infusion Site Directory
Infusion sites can enroll in the Teva National Infusion Site Directory. Once registered, Teva Support Solutions
® will be able to share information about the infusion site with healthcare providers who are looking for infusion sites for their CINQAIR ® patients.
The information can include address, hours of operations, insurance plans accepted, and infusion site amenities.
To begin the enrollment process, visit
Get connected to Teva Support Solutions
Call , 1-844-838-2211 Monday–Friday, 9AM–7PM ET
INDICATIONS AND USAGE
CINQAIR (reslizumab) Injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Limitations of Use: CINQAIR is not indicated for:
treatment of other eosinophilic conditions
relief of acute bronchospasm or status asthmaticus
IMPORTANT SAFETY INFORMATION
Anaphylaxis has been observed with CINQAIR infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR.
Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis.
IMPORTANT SAFETY INFORMATION (continued)
CINQAIR is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients.
WARNINGS AND PRECAUTIONS
Acute Asthma Symptoms or Deteriorating Disease: CINQAIR should not be used to treat acute asthma symptoms or acute exacerbations. Do not use CINQAIR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with CINQAIR.
Malignancy: In placebo-controlled clinical studies, 6/1028 (0.6%) patients receiving 3 mg/kg CINQAIR had at least 1 malignant neoplasm reported compared to 2/730 (0.3%) patients in the placebo group. The observed malignancies in CINQAIR-treated patients were diverse in nature and without clustering of any particular tissue type. The majority of malignancies were diagnosed within less than six months of exposure to CINQAIR.
Reduction of Corticosteroid Dosage: No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of CINQAIR. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with CINQAIR. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection: Eosinophils may be involved in the immunological response to some helminth infections. Treat patients with pre-existing helminth infections before initiating CINQAIR. If patients become infected while receiving treatment with CINQAIR and do not respond to anti-helminth treatment, discontinue treatment with CINQAIR until infection resolves.
Adverse reactions that occurred at ≥2% incidence and more commonly than in the placebo group included 1 event: oropharyngeal pain (2.6% vs. 2.2%).
Elevated baseline creatine phosphokinase (CPK) was more frequent in patients randomized to CINQAIR (14%) versus placebo (9%). Transient CPK elevations in patients with normal baseline CPK values were observed more frequently with CINQAIR (20%) versus placebo (18%) during routine laboratory assessments.
Myalgia was reported in 1% (10/1028) of patients in the CINQAIR 3 mg/kg group compared to 0.5% (4/730) of patients in the placebo group.
Immunogenicity: In placebo-controlled studies, a treatment-emergent anti-reslizumab antibody response developed in 53/983 (5.4%) of CINQAIR-treated patients (3 mg/kg). The antibody responses were of low titer and often transient. There was no detectable impact of the antibodies on the clinical pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of CINQAIR.
, including Boxed WARNING for CINQAIR full Prescribing Information ®.
YOU ARE ABOUT TO LEAVE THIS SITE
You are about to leave TEVAsupportsolutions.com and enter a website operated by a third party.
Would you like to continue?